Bristol’s Mavacamten Shows Consistent Efficacy, Safe Use In Obstructive HCM At ACC

US FDA Decision On First Indication Due On 28 April

Long-term results from the EXPLORER-HCM extension study are consistent with the pivotal trial in obstructive hypertrophic cardiomyopathy, while data from VALOR may support a supplemental filing.

Heart shaped pills on a black background
Oral pill mavacamten is pending US FDA approval at the end of April • Source: Alamy

Bristol Myers Squibb Company has high expectations for its first-in-class cardiac myosin inhibitor mavacamten in hypertrophic cardiomyopathy (HCM), with peak annual sales predicted at more than $4bn. The company presented data at the American College of Cardiology (ACC) Scientific Sessions on 2 and 3 April in obstructive HCM (oHCM) that may help BMS make the case for strong commercial use of the drug based on safety and efficacy in a long-term study and in patients with more advanced disease.

Bristol’s multibillion-dollar sales estimate for mavacamten is based on multiple indications. The US Food and Drug Administration is reviewing the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By 

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.